Clinical utility of anti-cytosolic 5’-nucleotidase 1A antibody in idiopathic inflammatory myopathies

Keyphrases

• Clinical Utility 100%
• Idiopathic Inflammatory Myopathies 100%
• Cytosolic 5′-nucleotidase 1A 100%
• Inclusion Body Myositis 85%
• Seropositivity 42%
• Dermatomyositis 42%
• Antisynthetase Syndrome 42%
• Noninflammatory 28%
• Muscle Disease 28%
• Myositis 28%
• Malignancy 14%
• Diagnostic Utility 14%
• Disease Response 14%
• University of Washington 14%
• Prognostic Factors 14%
• Cytochrome Oxidase 14%
• Clinical Laboratory 14%
• Response to Treatment 14%
• Interstitial Lung Disease 14%
• Antibody Status 14%
• Prognostic Survival 14%

Medicine and Dentistry

• Inclusion Body Myositis 100%
• Myositis 100%
• 5' Nucleotidase 100%
• Immunity 50%
• Myopathy 50%
• Dermatomyositis 50%
• Antisynthetase Syndrome 50%
• Muscle Disease 33%
• Diagnosis 16%
• Cancer 16%
• Prognostic Factor 16%
• Cytochrome C Oxidase 16%
• Interstitial Lung Disease 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Myositis 100%
• Inclusion Body Myositis 100%
• 5' Nucleotidase 100%
• Myopathy 50%
• Dermatomyositis 50%
• Antisynthetase Syndrome 50%
• Muscle Disease 33%
• Interstitial Lung Disease 16%
• Cytochrome C Oxidase 16%